Eli Lilly and Company has officially broken ground on a $3.5 billion manufacturing facility in Pennsylvania's Lehigh Valley. The site, which is part of a broader $50 billion U.S. expansion, is designed to produce next-generation obesity treatments, including the investigational drug retatrutide. The project is expected to create 850 high-wage jobs and 2,000 construction roles, with operations slated to begin by 2031.
Neutral
🤖 60%
Lilly broke ground on a $3.5 billion Pennsylvania plant on Nov. 12, 2026 for injectable obesity medicines including retatrutide, within its previously announced $50 billion U.S. expansion. The site creates 850 jobs and is only expected to be operational by 2031, so no near-term revenue or earnings change; the investment itself was already part of the announced plan.
Catalysts
- • Groundbreaking of $3.5 billion Lehigh Valley facility announced Nov. 12, 2026
- • Capacity earmarked for next-generation obesity treatments including retatrutide, in Phase 3 trials
Risk Factors
- • Facility not operational until 2031, so no near-term production benefit
- • Retatrutide is still investigational and cannot be legally sold, so pipeline outcome remains uncertain